Patient recruitment has started in a randomised clinical trial testing an experimental device (Lamelleye, known also as CXB/1-14) for the treatment of dry eye disease (DED).
A total of 30 patients will be enrolled at Glasgow Caledonian University’s Vision Sciences clinic, in Glasgow, UK, according to a press release from the company behind the device, Lamellar Biomedical, which is also based in Glasgow.
The firm expects to report results in the second half of 2017, as well as attract a licensing partner to help it bring the product to the European market in 2018.
“We believe that Lamelleye has the potential to be an important advance in the treatment of DED,” Lamellar CEO Dr Alec McLean said.
The product is designed to replace ocular lipid layer phospholipids, which are generated by the lacrimal gland and meibomian glands in the eyelids and are produced in insufficient quantities in DED.
When these lipids are lacking, the aqueous layer evaporates, causing symptoms of burning and grit-like feelings in the eye. Long-term dry eye can lead to damage to the cornea, including scarring that can interfere with vision.